Rheumatoid Arthritis Market

Global Rheumatoid Arthritis Market is valued at USD 28,442.5 Million in 2021 and is expected to reach USD 38,786.6 Million by 2028 with a CAGR of 5.0% over the forecast period.

Global Rheumatoid Arthritis Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2022-2029: Rise in the prevalence of rheumatoid arthritis, increasing product launches by the key players, and rising approvals of biosimilars for the treatment of rheumatoid arthritis are some of the major factors driving the growth of the Rheumatoid Arthritis Market

Scope-

Rheumatoid Arthritis (RA) is a regressive polyarthritis that develops from intermediate to more proximal joints and is characterized by persistent pain and joint deterioration. RA is a chronic, inflammatory autoimmune disease. The precise origins of Rheumatoid Arthritis are still unknown; however, it is assumed that Rheumatoid Arthritis results from an immunological reaction in which the body's immune system assaults its own healthy cells. About 75% of Rheumatoid Arthritis patients are women, who are more likely to develop the disease. Rheumatoid arthritis can affect 1 to 3 percent of women at some point in their lives.

The disorder most often begins between the ages of 30 and 50. However, RA can start at any age. Rheumatoid Arthritis is a chronic condition that impairs joint mobility and produces stiffness, swelling, and discomfort in the joints. The hands and feet's small joints are most frequently impacted. Other organs, such as the eyes, skin, or lungs, might occasionally also be impacted by Rheumatoid Arthritis.

The diagnosis of the patient, the analyses of the medical assessment, the evaluation of risk factors, family history, a joint evaluation by ultrasound sonography, and the evaluation of laboratory markers, such as elevated levels of CRP and ESR in serum and the detection of RA-specific autoantibodies, are typically used to diagnose RA.

Traditional DMARDs are a class of medications (including methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine) that have been demonstrated to influence the underlying cause of RA by reducing immune system hyperactivity. This reduces pain, swelling, and stiffness while also preventing changes from occurring within the joints. Methotrexate (MTX), one of the csDMARDS, is regarded as a component of the first therapy plan. In addition to being used as monotherapy, MTX continues to be the cornerstone medication for RA. It serves as the foundation for combination treatments, either with GC or with additional csDMARDs, bDMARDs, or tsDMARDs.

COVID-19 Impact-

Due to the increased incidence of COVID-19 infection among rheumatoid arthritis (RA) patients, COVID-19 has a substantial influence on the rheumatoid arthritis market. For instance, patients with rheumatoid arthritis (RA) were more likely than those without RA to develop COVID-19 and severe COVID-19 (which can result in hospitalization or death), according to the study "Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals" published in October 2021.

Additionally, the research "The COVID-19 pandemic: an elevated risk of rheumatoid arthritis" released in June 2021 found that people prone to RA had a higher infection risk than the general population due to the autoimmune side effects of RA-related pharmaceutical therapy. Therefore, a COVID-19 pandemic might raise the possibility of a health emergency in illnesses like RA that are complex. As a result of these incidences, COVID-19 infection significantly affected the rheumatoid arthritis market over the forecast period.

Key Players-

The prominent players operating in this marketplace are -

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• UCB S.A.
• Johnson & Johnson Services Inc.
• others

Segmentation-

By Molecule:

• Pharmaceuticals

  • NSAIDs
  • Analgesics
  • DMARDs
  • Glucocorticoids

• Biopharmaceuticals

  • Biologics

    • TNF-α antagonists
    • T-cell inhibitors
    • CD20 antigen
    • JAK inhibitors
    • anti-IL6 biologics

  • Biosimilars

    • CD20 antigen
    • TNF-α antagonists

By Drug Class:

• Disease-modifying Anti-rheumatic Drugs (DMARDs)
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Uric Acid Drugs
• Others

By Route Of Administration:

• Oral
• Parenteral

By Sales Channel:

• Prescription-based Drugs
• Over-the-counter Drugs

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Market Drivers-

The Rise in Prevalence of Rheumatoid Arthritis is Expected to Boost Market Growth:

The global prevalence of rheumatoid arthritis (RA) was calculated to be 0.46 percent, according to research that was published in Rheumatology International in November 2020 with the title "The global prevalence of rheumatoid arthritis (RA): a meta-analysis based on a systematic review." Furthermore, Rheumatoid arthritis is one of the leading causes of disability in the Middle East and Africa. According to a comprehensive research and meta-analysis on the topic released by Stellenbosch University in South Africa, the prevalence of RA is estimated to be 0.3% in Egypt and 0.4% in Lesotho. This will lead to the rising adoption of therapies for RA treatment and thus drive the market’s growth during the forecast period.

Increasing Product Launches by The Key Players and Rising Approvals of Biosimilars for The Treatment of Rheumatoid Arthritis are Expected augment industry outlook

Rising product launches by industry participants are anticipated to accelerate market expansion. To treat individuals with active rheumatoid arthritis, for instance, Lupin introduced generic leflunomide in the United States in September 2020. The market will rise as a result of people using rheumatoid treatments more frequently. Additionally, increasing approvals of biosimilars for the treatment of rheumatoid arthritis also supports market expansion. For instance, Cyltezo was authorized by the US Food and Drug Administration in October 2021. One of the first Humira interchangeable biosimilars to treat rheumatoid arthritis is introduced.

Market Restraints-

High Costs Associated with Treatment for Rheumatoid Arthritis Expected to Hinder market expansion

Biologic therapies for rheumatoid arthritis are more effective than conventional DMARDs in this aspect, with two out of three patients responding to them. However, the cost each month for these drugs might range from US$ 1000 to US$ 3000. The out-of-pocket expenses are high even if the patient has a great health insurance plan as it may not always cover biologics. Therefore, the high cost of therapy is the key factor restricting the rate of biologics treatment and, subsequently, restricting the market growth.

The Institute for Clinical and Economic Analysis, 2021 states that the price of Humira has climbed from $19,000 per year (in 2012) to more than $38,000 per year (in 2019). One of the reasons for the high cost of rheumatoid arthritis treatment is the broad variation in symptoms across patients, independent of age, and the stage of the illness at which symptoms first appear.

For instance, according to survey findings from Medlink U.K., 75% of RA patients have a variety of symptoms such as joint discomfort, swelling, and flare-ups, 20% have relatively moderate instances of the illness, and just 5% advance to a severe form with deformities. The 5% of patients who show very little activity and require extended therapy are a major contributor to the treatment's high cost. This 5% of patients in Europe cost the government in the region US$ 5.2 billion per year.

Thus, the high costs associated with treatment for rheumatoid arthritis are expected to hinder market expansion in the coming year.

Geography Analysis-

North America is expected to Capture a Major Share of the Global Rheumatoid Arthritis Market:

North America is anticipated to hold a considerable share of the rheumatoid arthritis market and is anticipated to continue to exhibit the same trend over the forecast period. The rising prevalence of the disease, the dominance of key market players, the increased introduction of novel therapies including monoclonal antibodies for rheumatoid arthritis, and rising market key players’ investments in research for the development of novel treatments and biosimilars for this disease are all factors that expected to boost the market in the coming year.

The Center for Disease Control and Prevention (CDC) estimate that about 1 in 4 individuals in the United States (23.7%), or 58.5 million people, will have arthritis as determined by a medical professional in October 2021. Additionally, the Government of Canada estimates that in September 2020, there will be around 374,000 (1.2%) Canadians aged 16 and older who have rheumatoid arthritis. This disorder is so widely prevalent that there is a high need for pharmaceuticals to treat it, which in turn propels market expansion.

As a result of the aforementioned factors, the market for rheumatoid arthritis in the North American region is anticipated to increase throughout the projected period.

Asia Pacific Rheumatoid Arthritis Market Is Expected to Grow At A Considerable Pace Over The Forecast Period:

Due to the large population base susceptible to rheumatoid arthritis, increased public awareness of the use and benefits of these drugs, development of the R&D sector, rise in healthcare reforms, and increased adoption of rheumatoid arthritis drugs, Asia-Pacific offers lucrative opportunities for key players operating in the rheumatoid arthritis drugs market. Additionally, the elderly population growth and rising DMARD demand both contribute to the market's expansion. The market for rheumatoid arthritis medications is also anticipated to rise in the region as a result of prominent manufacturers' increased focus on increasing their geographic presence in developing Asia-Pacific nations.

News-

• The Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb), an interchangeable biosimilar to Humira, was accepted for evaluation by the US Food and Drug Administration (FDA) in February 2022.
• To develop, produce, and market Xcimzane, Biogen Inc. and Xbrane Biopharma AB signed a commercialization and license deal in February 2022. This preclinical monoclonal antibody is a putative biosimilar of the rheumatoid arthritis drug CIMZIA (certolizumab pegol).

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2021:	USD 28,442.5 Million
Base year considered	2021
Forecast Period CAGR %:	5.0%
Market Size Expected in 2028:	USD 38,786.6 Million
Tables, Charts & Figures:	175
Pages	300
Companies	AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Pfizer, Inc., F. Hoffmann-La Roche Ltd., UCB S.A., Johnson & Johnson Services, Inc., and others
Segments Covered	By Molecule, By Drug Class, By Route Of Administration, By Sales Channel
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa